ERS International Congress, Milan 2017

Browse by day: Saturday, 09.09.2017 Sunday, 10.09.2017 Monday, 11.09.2017 Tuesday, 12.09.2017 Wednesday, 13.09.2017		Sponsored symposia: Industry Evening Symposium at ERS 2017: “Evolving Concepts in Asthma with Type 2 Inflammation: the Role of Biologics”

Citations should be made in the following way: Authors. Title. Eur Respir J 2017; 50: Suppl. 61, abstract number.

Oral Presentation
Chairs: L. Rubin (New York, United States of America), O. Sitbon (Le Kremlin-Bicêtre, France)

Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study M. Hoeper (Hannover, Germany)
Pulmonary arterial hypertension-related morbidity is prognostic for survival: insights from the SERAPHIN and GRIPHON studies M. Hoeper (Hannover, Germany)
Iron carboxymaltose improves exercise tolerance and right heart strain in patients with PAH and iron deficiency: A long-term pilot study T. Kramer (Köln, Germany)
The ARROW Study: A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of Selonsertib in Subjects with Pulmonary Arterial Hypertension G. Brooks (Foster City, United States of America)
Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study G. Simonneau (Le Kremlin-Bicêtre, France)
RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia S. Nathan (Falls Church, United States of America)
Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL R. Benza (Pittsburgh, United States of America)